Novartis has signed an agreement to divest its 'front of eye' ophthalmology assets to Bausch + Lomb, a global eye health company. The transaction is valued at up to $2.5...
13.05.2019
- To lighten its debt burden of more than $30 billion resulting from last year’s acquisition of Shire, Japanese pharma giant Takeda is selling Shire’s dry-eye drug Xiidra to...
